Top

Reactions Weekly

Published in:

01-01-2024 | Cutaneous Squamous Cell Carcinoma | Case report

Cemiplimab

Subacute cutaneous lupus erythematosus and immune-related hepatitis

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Fietz S, et al. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report. Frontiers in Immunology 14: Jan 2023. Available from: URL: https://dx.doi.org/10.3389/fimmu.2023.1324231

Title: Cemiplimab
Subacute cutaneous lupus erythematosus and immune-related hepatitis
Publication date: 01-01-2024
Publisher: Springer International Publishing
Keywords: Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Lupus Erythematosus
Hepatitis
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-52578-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cemiplimab

Subacute cutaneous lupus erythematosus and immune-related hepatitis

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Pembrolizumab

No causal link between GLP-1 RAs and suicidal ideation

Multiple drugs

Elasomeran/Methylprednisolone

Multiple drugs

Leflunomide/methotrexate